# Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

> **NCT03238781** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 343 (actual)

## Conditions studied

- Chronic Migraine or Episodic Migraine

## Interventions

- **DRUG:** Placebo
- **DRUG:** AMG 301

## Key facts

- **NCT ID:** NCT03238781
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-06
- **Primary completion:** 2018-10-16
- **Final completion:** 2019-02-04
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238781, "Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03238781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*